Form 4: Centessa Pharmaceuticals Director Granted 40,000 Share Options

Centessa Pharmaceuticals plc Director Carol Stuckley has been granted 40,000 share options with an exercise price of $12.43, aligning her interests with long-term shareholder value.

Summary

• Carol Stuckley, a Director at Centessa Pharmaceuticals plc (CNTA), was granted 40,000 share options.
• The options have an exercise price of $12.43 per share.
• These options are exercisable immediately upon vesting, which occurs on the earlier of June 20, 2026 (one year from grant date) or the company's next annual meeting of shareholders.
• The options expire on June 20, 2035.
• Vesting is contingent upon Carol Stuckley's continued service as a director.

Sentiment

Score: 6

Explanation: The grant of share options to a director is a standard compensation practice that aligns the director's financial interests with the long-term performance of the company's stock, which is generally viewed as a positive for corporate governance and shareholder value.

Positives

• The grant of 40,000 share options to Director Carol Stuckley aligns her interests with those of shareholders, as the options gain value if the stock price increases above the $12.43 exercise price.
• The long expiration date of June 20, 2035, provides a significant window for the options to become in-the-money, incentivizing long-term performance.

Negatives

• No specific negative information is contained within this Form 4 filing, as it primarily reports a routine compensation event.

Risks

• The value of the share options is subject to the future performance of Centessa Pharmaceuticals plc's stock price; if the stock price does not exceed the $12.43 exercise price, the options may expire worthless.
• Vesting of the options is contingent on continued service as a director, meaning the options could be forfeited if service ceases before the applicable vesting date.

Future Outlook

The vesting schedule for the share options, contingent on continued service, indicates an expectation of Carol Stuckley's ongoing role as a director for at least the next year or until the next annual meeting. The long expiration date suggests a long-term incentive for performance.

Industry Context

The grant of share options is a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align the interests of leadership with long-term shareholder value creation. This practice is standard across publicly traded companies, particularly those in growth-oriented sectors like pharmaceuticals.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, including those in the pharmaceutical sector.
• While the specific number of options (40,000) and exercise price ($12.43) are specific to Centessa Pharmaceuticals plc and Director Stuckley's compensation package, such grants are generally benchmarked against peer companies' compensation structures for similar roles.
• Without specific compensation data for comparable directors at companies like AstraZeneca, GlaxoSmithKline, or smaller biotech firms with similar market caps and development stages, a direct quantitative comparison is not feasible from this document alone.
• However, the mechanism of granting options with a vesting schedule and a long expiration period is consistent with industry norms designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with shareholder interests, as the options gain value only if the company's stock price increases above the exercise price.

Next Steps

• The share options will vest on the earlier of June 20, 2026, or the Issuer's next annual meeting of shareholders, subject to continued service.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Share Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Pharmaceuticals, Biotechnology